Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛羅里達州奧蘭多/ACCESSWIRE/2023 年 9 月 22 日/ RedChip Companies將於美國東部時間9月23日星期六晚上7點在彭博電視臺贊助的節目《紅籌財經報告》上播出對Reviva Pharmicals Holdings, Inc.（納斯達克股票代碼：RVPH）和Aridis Pharmicals, Inc.（場外交易代碼：ARDS）的採訪。據估計，彭博電視在美國有7300萬個家庭中播出。
Access the interviews in their entirety at:
訪問訪談的全部內容，請訪問：
- Reviva Pharmaceuticals:
- Aridis Pharmaceuticals:
- Reviva 藥業：
- 艾瑞迪斯製藥公司：
About The RedChip Money Report
關於《紅籌理業績告》
The RedChip Money Report is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today. "The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
RedChip Money Report由RedChip Companies Inc. 製作，該公司是一家擁有30年經驗的國際投資者關係和媒體公司，專注於 今天發現明天的藍籌股。“RedChip Money Report》對小盤股投資發表了深刻的評論、對華爾街分析師的採訪、金融書評以及對上市公司高管的精選訪談。
About Reviva Pharmaceuticals Holdings, Inc.
關於 Reviva 製藥控股有限公司
Reviva is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.
Reviva是一家處於後期階段的製藥公司，它發現、開發下一代療法並將其商業化，這些療法代表着未得到滿足的醫療需求和社會、患者及其家庭的負擔。Reviva目前的產品線側重於中樞神經系統、炎症和心臟代謝疾病。Reviva的產品線目前包括兩種候選藥物，RP5063（brilaroxazine）和 RP1208。兩者都是內部發現的新化學實體。Reviva 已在美國（美國）、歐洲和其他幾個國家獲得 RP5063 和 RP1208 的物質組成專利。
About Aridis Pharmaceuticals, Inc.
關於 Aridis 製藥有限公司
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. The Company is utilizing its proprietary ʎPEX and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture mAbs for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose and do not require further engineering optimization to achieve full functionality.
Aridis Pharmicals, Inc. 發現並開發了抗感染藥物，用作對抗抗微生物藥物耐藥性（AMR）和病毒疫情的一線治療方法。該公司正在利用其專有的 “pex” 和 “mabiGX” 技術平台，從成功克服感染的患者身上快速鑑定出罕見的、產生強效抗體的B細胞，並快速製造用於治療危重感染的單克隆抗體。這些單克隆抗體已經起源於人類，經過人體自然免疫系統的功能優化，具有很高的效力。因此，它們已經適合用途，不需要進一步的工程優化即可實現全部功能。
The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antibacterial and antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care, which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.
除了臨床前階段的抗菌和抗病毒單克隆抗體外，該公司還生產了多種針對導致危及生命的感染的細菌的臨床階段單克隆抗體，例如呼吸機相關性肺炎（VAP）和醫院獲得性肺炎（HAP）。使用單克隆抗菌作爲抗感染療法代表了一種創新的治療方法，它利用人類免疫系統來對抗感染，旨在克服與當前護理標準（廣譜抗生素）相關的缺陷。此類缺陷包括但不限於耐藥性增加、療效持續時間短、人類微生物組正常菌羣中斷以及當前治療方法之間缺乏區別。mAb 產品組合輔之以一種非抗生素新機制的小分子抗感染候選藥物，用於治療囊性纖維化患者的肺部感染。
About RedChip Companies
關於紅籌公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家Inc. 5000公司，是一家國際投資者關係、媒體和研究公司，專注於微型股和小盤股公司。30年來，RedChip爲其客戶提供了具體、可衡量的結果。我們的時事通訊《RedChip Money Report》每週在線發佈給6萬名投資者。RedChip 爲微型股和小型股公司開發了業內最全面的服務平台。這些服務包括：股票研究的全球分銷網絡；在美國主要城市的零售和機構路演；向股票經紀商、區域投資機構、機構和家族辦公室進行境外營銷；產生了數百萬個獨特投資者觀點的數字媒體投資者關係平台；投資者網絡研討會和小組會議；每週在美國彭博社播出的電視節目 “RedChip Money Report》；本地和國內市場的電視廣告；公司和產品視頻；網站設計；和傳統投資者關係服務，包括新聞稿寫作、投資者演示文稿編寫、季度電話會議腳本寫作、戰略諮詢、融資等。
To learn more about RedChip's products and services, please visit:
要了解有關RedChip產品和服務的更多信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“今天發現明天的藍籌股”
Contact:
聯繫人：
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com
戴夫·金特里
RedChip Companies
1-800-RED-CHIP (733-2447)
或 407-491-4498
info@redchip.com
SOURCE: RedChip
來源： RedChip
譯文內容由第三人軟體翻譯。